Echo Therapeutics’s Needle-Free Symphony Continuous Glucose Monitoring System Featured in Diabetes Health Magazine

FRANKLIN, Mass., Nov. 30, 2010 /PRNewswire/ -- Echo Therapeutics, Inc. (OTC Bulletin Board: ECTE), a company developing its needle-free Symphony tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system and its Prelude SkinPrep System for transdermal drug delivery, today announced that its Symphony System was profiled in the November 29, 2010 issue of Diabetes Health magazine.

The article can be found at: http://www.diabeteshealth.com/read/2010/11/29/6962/echo-therapeutics-needle-free-symphony-continuous-glucose-monitoring-system/.

The article discusses the Symphony continuous glucose monitoring system as potentially the first “noninvasive” glucose monitor to successfully come to the market. According to the article, “The need in the market is great right now for both patients and medical professionals to use in their practices and in surgeries. The days of having to use a needle to test blood glucose are numbered, and the need for an effective continuous monitoring system is becoming increasingly essential as the number of patients with diabetes grows.”

Diabetes Health has a total circulation of 150,000, including 25,000 digital subscribers, 25,000 paid consumers and a 100,000-member “controlled and qualified Direct-to-Patient Circulation Program.” The Direct-to-Patient Circulation Program is requested by and distributed to a controlled and qualified list of certified diabetes educators, physicians and nurses. They in turn give Diabetes Health to 100,000 newly diagnosed patients as an educational tool every two months.

“We are pleased to be recognized and have our innovative Symphony system profiled in Diabetes Health magazine, long recognized as one of the leading authorities on managing diabetes,” commented Patrick T. Mooney, M.D., Chairman, President and CEO of Echo. “Diabetes authorities are increasingly embracing the need for continuous glucose monitoring as a way to more effectively manage the disease, and Symphony represents the first proven non-invasive method for ensuring continuous monitoring. In addition, Symphony replaces the painful use of a needle to test blood glucose, improving the quality of life for diabetics.”

About Echo Therapeutics

Echo is developing the Symphony tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system for patients with diabetes and for use in hospital critical care units. Echo is also developing its needle-free Prelude SkinPrep System as a platform technology for enhanced skin permeation for delivery of topical pharmaceuticals.

Cautionary Statement Regarding Forward Looking Statements

The statements in this press release that are not historical facts may constitute forward-looking statements that are based on current expectations and are subject to risks and uncertainties that could cause actual future results to differ materially from those expressed or implied by such statements. Those risks and uncertainties include, but are not limited to, risks related to regulatory approvals and the success of Echo’s and its partners’ ongoing studies, including the efficacy of Echo’s Symphony tCGM and Prelude SkinPrep Systems, the failure of future development and preliminary marketing efforts related to Echo’s Symphony tCGM and Prelude SkinPrep Systems, Echo’s ability to secure additional commercial partnering arrangements, risks and uncertainties relating to Echo’s and its partners’ ability to develop, market and sell diagnostic and transdermal drug delivery products based on its skin permeation platform technologies, including the Symphony tCGM and Prelude SkinPrep Systems, the availability of substantial additional equity or debt capital to support its research, development and product commercialization activities, and the success of its research, development, regulatory approval, marketing and distribution plans and strategies, including those plans and strategies related to its Symphony tCGM and Prelude SkinPrep Systems. These and other risks and uncertainties are identified and described in more detail in Echo’s filings with the Securities and Exchange Commission, including, without limitation, its annual report on Form 10-K for the year ended December 31, 2009, its quarterly reports on Form 10-Q, and its current reports on Form 8-K. Echo undertakes no obligation to publicly update or revise any forward-looking statements.

SOURCE Echo Therapeutics, Inc.